Valneva SE announced on June 4, 2025, that Mr. Franck Grimaud, Chief Business Officer and one of the company's co-founders, will leave Valneva on June 25, 2025. His departure marks the end of a 26-year tenure with Vivalis and Valneva, during which he contributed to the company's development and commercial vaccine business.
Thomas Lingelbach, CEO of Valneva, acknowledged Mr. Grimaud's significant contributions to the company's strategy and commercial operations. The announcement was made in conjunction with the availability of documentation for the company's Combined General Meeting.
This leadership change comes at a pivotal time for Valneva as it navigates regulatory challenges for its chikungunya vaccine and advances its Lyme disease candidate. Investors will be watching for how the company manages this transition and its potential impact on future business development and commercial strategy.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.